Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer (Q36667452)

15 August 2017

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer (English)

1 reference

15 August 2017

phase III clinical trial

0 references

1 reference

1 reference

1 reference

L Paz-Ares

1

1 reference

15 August 2017

H Ross

2

1 reference

15 August 2017

M O'Brien

3

1 reference

15 August 2017

A Riviere

4

1 reference

15 August 2017

U Gatzemeier

5

1 reference

15 August 2017

J Von Pawel

6

1 reference

15 August 2017

E Kaukel

7

1 reference

15 August 2017

L Freitag

8

1 reference

15 August 2017

W Digel

9

1 reference

15 August 2017

H Bischoff

10

1 reference

15 August 2017

R García-Campelo

11

1 reference

15 August 2017

N Iannotti

12

1 reference

15 August 2017

P Reiterer

13

1 reference

15 August 2017

I Bover

14

1 reference

15 August 2017

J Prendiville

15

1 reference

15 August 2017

A J Eisenfeld

16

1 reference

15 August 2017

F B Oldham

17

1 reference

15 August 2017

B Bandstra

18

1 reference

15 August 2017

J W Singer

19

1 reference

15 August 2017

P Bonomi

20

1 reference

15 August 2017

language of work or name

English

0 references

publication date

13 May 2008

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

98

1 reference

15 August 2017

10

1 reference

15 August 2017

1608-1613

1 reference

15 August 2017

Cancer statistics, 2007

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391114

In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391114

Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391114

Erlotinib in previously treated non-small-cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391114

Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391114

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391114

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391114

Cathepsin B and its role(s) in cancer progression

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391114

Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391114

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391114

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391114

Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391114

A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391114

Design and analysis of non-inferiority mortality trials in oncology.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391114

Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391114

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391114

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2391114

20 September 2018

Identifiers

DOI

10.1038/SJ.BJC.6604372

1 reference

Dimensions Publication ID

15 August 2017

1043127203

0 references

Fatcat ID

release_6oqyb4wftndghcqwnnfrx7wh2y

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6oqyb4wftndghcqwnnfrx7wh2y

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

15 August 2017

PubMed publication ID

18475293

1 reference